Aptuit (Oxford) Limited

Organisation type
Mr Paul Overton
President, Business Development 

CIMYM BioSciences

Organisation type
Ms Yvonne Joseph
Managing Director 

CLINICAL ACCELERATOR

Organisation type
Keywords
contract research
Mr NIKOLAI NIKITIN
Director 

Cresset Discovery Services

Organisation type
Mr Carlton Squires
Account Manager 

Crystec Ltd.

Organisation type
Ms Catherine Hunter
Business Development Director 
Mr Paul Thorning
CEO 

HungaroTrial

Organisation type
Mr Roope Ghosh

Image Analysis

Organisation type
Keywords
imaging
Ms Diana Roettger
Head of Scientific and Medical Affairs 

Theradex Oncology

Organisation type
Dr Augustine Martin Smith
Medical Director 

XenoGesis

XenoGesis Ltd. is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has an enviable track record of delivery in drug discovery.

It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive pre-clinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies. Specifically,XenoGesis can identify the potential 'winners' and 'losers' in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.

Organisation type
Dr Rachel Hemsley
Global Head of Business Development